Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BeOne Medicines Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BeOne Medicines Ltd.'s regulatory disclosures and financial reporting.
Form 4 overview: On 18 Jun 2025, BeOne Medicines Ltd. (ticker ONC) reported a change in ownership by Senior Vice-President & General Counsel Henry Chan Lee.
- Transaction date: 16 Jun 2025
- Security sold: 422 American Depositary Shares (ADS)
- Price: US $266.50 per ADS
- Underlying shares: Each ADS represents 13 ordinary shares; sale equals 5,486 ordinary shares
- Reason: Mandatory tax-withholding sale linked to the vesting of a restricted share-unit (RSU) grant that began vesting 15 Jun 2023 (25 % annually)
- Post-sale holdings: 278,434 ordinary shares held directly; 0 ADS
No derivative transactions or additional disposals were reported. The filing indicates that unvested RSUs may accelerate under certain termination scenarios, but no acceleration occurred in this report.
Investor takeaway: The disposition is small relative to the executive’s remaining equity stake (≈2% of total direct holdings based on ADS equivalence) and was executed solely to satisfy tax obligations. No strategic signal or company-level financial data accompanies this filing.
Form 4 filing overview: BeOne Medicines Ltd. (ticker ONC) President & COO Xiaobin Wu reported three sales of the company’s American Depositary Shares (ADS) on 16-17 Jun 2025. Each ADS represents 13 ordinary shares.
- Shares sold: 2,173 ADS in total (1,443 ADS at $265.4695 weighted average, 100 ADS at $266.22, and 630 ADS at $250.8686).
- Proceeds: ≈ $555 thousand based on the disclosed prices.
- Reason: All sales were automatically executed under the mandatory tax-withholding feature of the executive’s Restricted Share Unit (RSU) agreements, coinciding with scheduled vesting dates.
- Residual ownership: After the transactions Wu still directly owns 1,246,047 ordinary shares and 0 ADS; indirectly, his spouse controls 4,000 ADS.
- Vesting schedule: The underlying RSUs vest 25 % annually from either 15 Jun 2023 or 16 Jun 2021, with accelerated vesting on certain termination events.
Investor take-away: The disposition represents <1 % of the executive’s economic exposure to ONC and was not discretionary trading. Accordingly, the filing is viewed as routine compliance rather than a signal of changing insider sentiment.
Form 4 Overview – BeOne Medicines Ltd. (ONC)
Chief Executive Officer and Director John Oyler filed a Form 4 covering two transactions executed on 16-17 June 2025. Both involved the company’s American Depositary Shares (ADS), each representing 13 ordinary shares.
- 16 Jun 2025: 3,680 ADS sold under transaction code “S” at a weighted-average price of $266.0452.
- 17 Jun 2025: 1,460 ADS sold under transaction code “S” at a weighted-average price of $256.4885.
Total ADS disposed: 5,140, equivalent to ≈66,820 ordinary shares. Gross proceeds, based on the reported weighted averages, amount to roughly $1.35 million.
The filing notes that both sales were automatically executed to cover mandatory tax-withholding obligations tied to the vesting of previously granted restricted share units (RSUs). They were not discretionary open-market sales.
Post-transaction holdings
- Direct holdings: 8,215,021 ordinary shares and 0 ADS.
- Indirect holdings (multiple trusts and entities): approximately 46 million ordinary shares, as detailed in five footnoted ownership vehicles. Oyler disclaims beneficial ownership of several of these positions.
No derivative security activity was reported. The transactions do not change Oyler’s board or executive status and appear administrative rather than strategic. Given the small proportion of shares sold relative to his overall beneficial ownership, market impact is likely limited.